MRK - Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today? | Benzinga
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive gastric/gastroesophageal junction cancer.
Cyramza (ramucirumab) is owned by Eli Lilly And Co (NYSE: LLY).
The prespecified interim analysis represents results from 54 randomized patients with second and third-line gastric/GEJ cancer, including a meaningful number of patients previously treated with AstraZeneca Plc's (NASDAQ: AZN) Enhertu (trastuzumab deruxtecan) and checkpoint inhibitors.
A ...